<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400787</url>
  </required_header>
  <id_info>
    <org_study_id>CP 04</org_study_id>
    <nct_id>NCT03400787</nct_id>
  </id_info>
  <brief_title>Latera RCT - Latera® Absorbable Nasal Implant vs. Sham Control for Lateral Nasal Valve Collapse</brief_title>
  <official_title>Latera RCT - Latera® Absorbable Nasal Implant vs. Sham Control for Lateral Nasal Valve Collapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirox, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirox, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the LATERA RCT is to demonstrate the superiority of the Latera
      Implant to improve nasal breathing, compared with a Sham Control procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the Latera Absorbable Nasal Implant (Latera Implant) Implant versus Sham Control
      in subjects with nasal valve collapse due to or primarily due to insufficient cartilaginous
      support of the lateral nasal wall.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be masked to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>Assessed 3 months post-procedure.</time_frame>
    <description>The primary endpoint of the study is the Responder Rate, assessed 3 months post-procedure in the per protocol population of the Latera and Sham arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate</measure>
    <time_frame>7 days, 30 days, and 6, 12, 18 and 24 months.</time_frame>
    <description>Responder Rate at 7 days, 30 days, and 6, 12, 18 and 24 months will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Nasal Valve Collapse</condition>
  <condition>Nasal Breathing</condition>
  <arm_group>
    <arm_group_label>Sham Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.
Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latera Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Latera Implant</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Sham Control Arm</arm_group_label>
    <arm_group_label>Latera Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet the following criteria to be included in the study:

          1. Adults aged 18 and above;

          2. Understands and provides written informed consent;

          3. Stated willingness to comply with all study procedures, post-treatment care and
             availability for the duration of the study follow up of 2 years;

          4. In good general health as evidenced by medical history;

          5. NOSE score ≥55;

          6. Dynamic bi-lateral nasal wall insufficiency as confirmed by Positive Modified Cottle
             Maneuver;

          7. Nasal and facial anatomy appropriate to receive the Latera Implant;

          8. Documented failure of benefit after at least 4 weeks of conservative medical
             management, including, for example, antihistamines or nasal steroids, evidenced by
             lack of efficacy or tolerability.

        Subjects meeting any one of the following criteria will be excluded for the study:

          1. Unable to tolerate or not a candidate for procedures performed under local anesthesia;

          2. Pathology other than lateral wall insufficiency (e.g. septal deviation, turbinate or
             adenoid hypertrophy, polyps, sinusitis, rhinitis) is the primary contributor to airway
             obstruction;

          3. Requires or is anticipated to require any other concurrent nasal procedures (e.g.
             Functional Endoscopic Sinus Surgery (FESS), rhinoplasty, sinuplasty, septoplasty, or
             turbinate reduction) outside of the index procedure within 12 months after the index
             procedure;

          4. FESS, sinuplasty, septoplasty, inferior turbinate reduction, or rhinoplasty within the
             past 6 months;

          5. Any other rhinoplasty procedures are planned or planned usage of external dilators
             within 24 months after the index procedure;

          6. Permanent nasal implant of any type (e.g. autologous, homologous, or synthetic graft)
             or dilator;

          7. Presence of concomitant inflammatory or infectious conditions or unhealed wounds in
             the treatment area (e.g., vestibulitis, vasculitis, active acne),

          8. Currently using chronic systemic steroids or recreational intra-nasal drugs;

          9. Currently has cancerous or pre-cancerous nasal lesions, has had radiation in the
             treatment area, or is currently receiving chemotherapy;

         10. History of a significant healing disorders including hypertrophic scarring, or keloid
             formation;

         11. Poorly controlled diabetes mellitus;

         12. Known or suspected allergy to PLA or other absorbable implant materials in the Latera
             Implant;

         13. Severe obstructive sleep apnea (OSA) and cannot or is unwilling to refrain from
             continuous positive airway pressure (CPAP) for up to 2 weeks post-procedure based on
             expected healing needs and mask types, in agreement with the treating physician;

         14. Female subjects, of child bearing potential, known or suspected to be pregnant or are
             lactating;

         15. Any other presenting condition that, in the medical opinion of the investigator, would
             disqualify the subject from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Stolovitzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ENT of Georgia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas Sidle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Facial Plastic Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Hebb</last_name>
    <phone>650-249-6379</phone>
    <email>ehebb@spiroxmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sacramento ENT</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vardenik Khalatyan</last_name>
      <phone>916-736-3399</phone>
      <email>vkhalatyan@sacent.com</email>
    </contact>
    <investigator>
      <last_name>Randall Ow, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Breathe Clear Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladys E Sager</last_name>
      <phone>310-372-0700</phone>
    </contact>
    <investigator>
      <last_name>Steven E Davis, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT of GA</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anisa Daftari, P.A</last_name>
      <phone>404-297-4230</phone>
      <email>anisa@daftaris.com</email>
    </contact>
    <investigator>
      <last_name>Pablo Stolovitzky, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Nasal and Sinus Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Pritikin</last_name>
      <phone>312-372-9335</phone>
      <email>bpritikin10@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jordan B. Pritikin, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michiana Sleep and ENT Solutions</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taimi Liepert</last_name>
      <phone>574-232-4800</phone>
      <email>tliepert@apom.com</email>
    </contact>
    <investigator>
      <last_name>Douglas Liepert, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany ENT &amp; Allergy</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Baum</last_name>
      <phone>518-701-2000</phone>
      <email>jbaum@albanyentandallergy.com</email>
    </contact>
    <investigator>
      <last_name>Gavin Setzen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont ENT</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Smith</last_name>
      <phone>336-768-3361</phone>
      <phone_ext>6</phone_ext>
      <email>ssmith@piedmontent.com</email>
    </contact>
    <investigator>
      <last_name>William Surry, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas ENT Specialist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Roberts, PA-C</last_name>
      <phone>281-492-7827</phone>
      <email>eroberts@TEXASENT.COM</email>
    </contact>
    <investigator>
      <last_name>Manish K Wani, TX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT Associates of Texas</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janel Shelton, P.A</last_name>
      <phone>972-731-7654</phone>
      <email>jshelton@berksonmedical.com</email>
    </contact>
    <investigator>
      <last_name>Neelesh Mehendale, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Facial Plastics and ENT</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia L. Bregman</last_name>
      <phone>210-468-5426</phone>
    </contact>
    <investigator>
      <last_name>Jose Barrera, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ogden Clinic</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Davis</last_name>
      <phone>801-726-3843</phone>
      <email>brittany.davis@ogdenclinic.com</email>
    </contact>
    <investigator>
      <last_name>Nadim B Bikhazi, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

